AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22305833
Drug: High-concentration oxygen
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration oxygen therapy
Trial: 30420324
Drug: Low-dose voclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose voclosporin (23.7 mg, twice daily)
Trial: 30420324
Drug: High-dose voclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose voclosporin (39.5 mg, twice daily)
Trial: 19164322
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg daily) for 6 months
Trial: 17882570
Drug: Additional cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional cycle of oral steroids
Trial: 17882570
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no further treatment
Trial: 14630595
Drug: Lingzhi (1.1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingzhi (1.1g single dose)
Trial: 14630595
Drug: Lingzhi (3.3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingzhi (3.3g acute dose)
Trial: 14630595
Drug: Lingzhi (0.72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingzhi (0.72 g/d for 10 days)
Trial: 12588694
Drug: Combination Low-Fat/High-FV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Low-Fat/High-FV diet
Trial: 9686497
Drug: Plasma adrenomedullin
RxNorm normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma adrenomedullin levels after treatment
Trial: 28741652
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine without morphine and postoperative rectus sheath bupivacaine
Trial: 28741652
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine with morphine and postoperative rectus sheath saline
Trial: 26109470
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (HbA1c <7.0%, blood pressure ≤135/85 mmHg, total cholesterol ≤3.5 mmol/L)
Trial: 23018531
Drug: Avagacestat 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat 15, 50, 100 or 150 mg once daily for 28 days (young men)
Trial: 23018531
Drug: Avagacestat 50
RxNorm normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat 50 mg and then 100 mg once daily for 14 days (elderly subjects)
Trial: 23018531
Drug: Avagacestat >50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat >50 mg/day
Trial: 8480264
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (PCA-M)
Trial: 8480264
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled intravenous narcotic analgesia (PCA-M) alone
Trial: 3099651
Drug: PSK oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK oral application plus Tegafur
Trial: 3099651
Drug: Tegafur oral
RxNorm normalized name: tegafur Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur oral administration only
Trial: 3099651
Drug: BRM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRM therapy (OK‐432 and PSK)
Trial: 26982618
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of H. sabdariffa calyx powder
Trial: 22394534
Drug: Daily TERT
RxNorm normalized name: TERT-572
DrugBank: TERT-572 (DB17286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TERT of 6‐12 hr
Trial: 22394534
Drug: Daily TERT
RxNorm normalized name: TERT-572
DrugBank: TERT-572 (DB17286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TERT of 12‐16 hr
Trial: 1683192
Drug: Hydroxyzine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine, 50 mg qhs
Trial: 2574555
Drug: Terfenadine, 60
RxNorm normalized name: Terfenadine, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 60 mg bid
Trial: 6119776
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg day-1 for 8 consecutive weeks
Trial: 31562043
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2 on days 1-28)
Trial: 31562043
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance chemotherapy (control group)
Trial: 30278489
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1 μg/kg (D1)
Trial: 30278489
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2 μg/kg (D2)
Trial: 17441846
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test with 15 microg Ni/cm(2) on large area
Trial: 17441846
Drug: Patch test
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch test at higher concentrations of nickel
Trial: 11692906
Drug: Iloprost (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (intravenous infusion)
Trial: 11692906
Drug: Nifedipine (oral)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (oral)
Trial: 3266379
Drug: ketorolac placebo/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac placebo/heparin placebo
Trial: 3266379
Drug: ketorolac active/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac active/heparin placebo
Trial: 3266379
Drug: ketorolac active/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac active/heparin active
Trial: 3266379
Drug: ketorolac placebo/heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac placebo/heparin active
Trial: 25503557
Drug: 1 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg/kg fentanyl (fent1 group)
Trial: 25503557
Drug: 2 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 µg/kg fentanyl (fent2 group)
Trial: 17620645
Drug: Household-based water
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household-based water treatment interventions
Trial: 12015391
Drug: t-PA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t-PA (100 mg intravenously over 15 minutes)
Trial: 31623051
Drug: LOP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOP chemotherapy (asparaginase + vincristine + dexamethasone) combined with IMRT
Trial: 31623051
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy (cyclophosphamide + pirarubicin + vincristine + dexamethasone) combined with IMRT
Trial: 31623051
Drug: LOP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOP chemotherapy combined with IMRT
Trial: 31623051
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy combined with IMRT
Trial: 27814309
Drug: Osteopathic Manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manipulative Medicine (OMM) bi-weekly for 6 weeks
Trial: 27814309
Drug: Weekly counseling
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly counseling sessions (placebo-control) for 6 weeks
Trial: 22021102
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (PTA plus SEP)
Trial: 18635705
Drug: Rivastigmine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (4.5 mg po bid) and domperidone (10 mg po qd)
Trial: 15044205
Drug: IFN‐gamma 1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐gamma 1b (200 microg) thrice weekly for 6 months
Trial: 15044205
Drug: IFN‐gamma 1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐gamma 1b treatment
Trial: 9862943
Drug: Admission to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission to the chest-pain observation unit (CPU) with a strict protocol including aspirin, heparin, continuous ST-segment monitoring, determination of creatine kinase isoenzyme levels, six hours of observation.
Trial: 8092082
Drug: diet relatively
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diet relatively high in fat + 30 mg dexfenfluramine (dF)
Trial: 30200973
Drug: Sequential POCUS-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential POCUS-assisted protocol
Trial: 22297080
Drug: Intraoperative antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements)
Trial: 22297080
Drug: Extended antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days)
Trial: 20501957
Drug: EPO (12,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO (12,000 IU intravenous administration)
Trial: 20501957
Drug: EPO (12,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO (12,000 IU intravenous administration) in LAD subgroup
Trial: 20501957
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline administration)
Trial: 9339268
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg t.i.d. xanomeline
Trial: 9339268
Drug: xanomeline (dose-dependent)
RxNorm normalized name: Xanomeline
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xanomeline (dose-dependent)
Trial: 8471827
Drug: Fluvoxamine (200-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200-300 mg/day)
Trial: 8471827
Drug: Maprotiline (200-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (200-300 mg/day)
Trial: 3535049
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pivampicillin and pivmecillinam
Trial: 29975601
Drug: High quantity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High quantity of carbohydrate (CHO) at 1.5 g/kg body weight
Trial: 29975601
Drug: Low quantity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low quantity of carbohydrate (CHO) at 0.8 g/kg body weight
Trial: 26822146
Drug: bexarotene 300
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bexarotene 300 mg
Trial: 17962429
Drug: varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varenicline 1 mg twice a day
Trial: 11206672
Drug: CODAS‐Verapamil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODAS‐Verapamil (200 mg)
Trial: 11206672
Drug: CODAS‐Verapamil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODAS‐Verapamil (300 mg)
Trial: 11206672
Drug: CODAS‐Verapamil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODAS‐Verapamil (400 mg)
Trial: 11206672
Drug: CODAS‐Verapamil (bedtime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODAS‐Verapamil (bedtime dosing)
Trial: 18237589
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose <81 mg/dl (hypoglycemia)
Trial: 18237589
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose >199 mg/dl (severe hyperglycemia)
Trial: 18237589
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose 81 to 99 mg/dl (euglycemic group)
Trial: 18237589
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose 81 to 99 mg/dl
Trial: 18237589
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose >199 mg/dl
Trial: 18237589
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose 150 to 199 mg/dl
Trial: 11863094
Drug: Original CISCA/VB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original CISCA/VB regimen (100% dose)
Trial: 11863094
Drug: Low-dose CISCA/VB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose CISCA/VB regimen (80% dose)
Trial: 10469180
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (single viral inactivated concentrate) - 32.5 IU kg-1
Trial: 10469180
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (double viral inactivated concentrate) - 27 IU kg-1
Trial: 7554704
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg for 1 day and 250 mg for 4 subsequent days
Trial: 7554704
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg twice daily for 12 days
Trial: 2177216
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 400 micrograms day‐1
Trial: 2177216
Drug: Inhaled nedocromil
RxNorm normalized name: nedocromil Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nedocromil sodium (NDS) 16 mg day‐1
Trial: 6986893
Drug: Bromocriptine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (after stopping therapy)
Trial: 23375753
Drug: Plant sterol-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-enriched margarine (3.0 g/d of plant sterols)
Trial: 23375753
Drug: Plant stanol-enriched
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol-enriched margarine (3.0 g/d of plant stanols)
Trial: 16969707
Drug: Rebeccamycin analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebeccamycin analog 500 mg/m2 IV bolus every 21 days (arm 1)
Trial: 16969707
Drug: Rebeccamycin analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebeccamycin analog 140 mg/m2 IV bolus daily x 5 days, every 21 days (arm 2)
Trial: 9261762
Drug: Theophylline with
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline with prednisone infusion
Trial: 9261762
Drug: Prednisone infusion
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone infusion alone
Trial: 25847553
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation group (TFG) - received two 500mg capsules of test formulation daily for 3 months
Trial: 21558566
Drug: High-calorie-expenditure (HCE)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie-expenditure (HCE) exercise (3,000-3,500 kcal/wk daily walking)
Trial: 20877184
Drug: Systemic hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic hypothermia (n = 46), induced within 10 hours after birth, decreasing rectal temperature to 33.5°C for 72 hours
Trial: 20877184
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n = 47)
Trial: 15342617
Drug: Frovatriptan 2.5
RxNorm normalized name: frovatriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan 2.5 mg oral dose
Trial: 9088589
Drug: GR117289C 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR117289C 10 mg
Trial: 9088589
Drug: GR117289C 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR117289C 100 mg
Trial: 9088589
Drug: GR117289C 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR117289C 300 mg
Trial: 8227803
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release nifedipine therapy
Trial: 3100446
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg BW carnitine daily as a continuous infusion over 16 h
Trial: 3100446
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg BW carnitine daily
Trial: 3259521
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol (average daily dose 160 mg)
Trial: 31805052
Drug: Intralesional meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional meglumine antimoniate therapy (IL‐MA)
Trial: 31805052
Drug: Endovenous meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endovenous meglumine antimoniate therapy (EV‐MA)
Trial: 25863828
Drug: 6-times-weekly home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-times-weekly home nocturnal hemodialysis
Trial: 25863828
Drug: 3-times-weekly hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-times-weekly hemodialysis (conventional arm)
Trial: 25863828
Drug: 6-month running
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month running treatment data analysis
Trial: 19429874
Drug: CIPII (Continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIPII (Continuous Intraperitoneal Insulin Infusion)
Trial: 3803413
Drug: Pinacidil (62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (62 +/- 18 mg/day)
Trial: 3803413
Drug: Hydralazine (128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (128 +/- 28 mg/day)
Trial: 28514309
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTA) 200 U subcutaneous injection, once daily at the painful area
Trial: 17519319
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml water
Trial: 17469765
Drug: 330 ml
RxNorm normalized name: ALCOHOL 247.5 mL in 330 mL EXTRACORPOREAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 ml beer per day for 30 consecutive days (EG)
Trial: 15206999
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not taking amiodarone or QT-prolonging drugs)
Trial: 12228873
Drug: Hormonal treatments
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatments
Trial: 9707042
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with ranitidine bismuth citrate (RBC) 400 mg b.i.d., clarithromycin 500 mg b.i.d., and metronidazole 500 mg b.i.d.
Trial: 9707042
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with ranitidine bismuth citrate (RBC) 400 mg b.i.d. and clarithromycin 500 mg b.i.d.
Trial: 9707042
Drug: Both triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both triple and dual therapy
Trial: 7793859
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine mesylate (400 mg)
Trial: 7793859
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine mesylate (800 mg)
Trial: 7793859
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine mesylate (1,200 mg)
Trial: 7793859
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine mesylate (1,600 mg)
Trial: 7793859
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine mesylate (all doses)
Trial: 2307239
Drug: FAM chemotherapy
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM chemotherapy plus aminoglutethimide/hydrocortisone (AG/HC) (250 mg bid AG + 20 mg bid HC)